Vaquero Private Wealth Ltd. Invests $989,000 in Thermo Fisher Scientific Inc. $TMO

Vaquero Private Wealth Ltd. acquired a new position in Thermo Fisher Scientific Inc. (NYSE:TMO) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 1,972 shares of the medical research company’s stock, valued at approximately $989,000.

Several other hedge funds have also made changes to their positions in TMO. J. Stern & Co. LLP raised its holdings in shares of Thermo Fisher Scientific by 58,006.4% in the fourth quarter. J. Stern & Co. LLP now owns 31,509,332 shares of the medical research company’s stock valued at $18,258,082,000 after acquiring an additional 31,455,105 shares in the last quarter. Norges Bank bought a new position in Thermo Fisher Scientific during the 4th quarter worth about $3,072,744,000. Auto Owners Insurance Co increased its position in Thermo Fisher Scientific by 57,845.0% during the 4th quarter. Auto Owners Insurance Co now owns 2,427,896 shares of the medical research company’s stock valued at $1,406,844,000 after purchasing an additional 2,423,706 shares during the period. T. Rowe Price Investment Management Inc. lifted its position in shares of Thermo Fisher Scientific by 2,183.2% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 1,328,845 shares of the medical research company’s stock worth $770,000,000 after purchasing an additional 1,270,643 shares during the period. Finally, Price T Rowe Associates Inc. MD increased its holdings in Thermo Fisher Scientific by 19.0% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 7,701,353 shares of the medical research company’s stock valued at $4,462,550,000 after buying an additional 1,230,872 shares during the period. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Thermo Fisher Scientific Price Performance

Shares of NYSE TMO opened at $588.17 on Monday. Thermo Fisher Scientific Inc. has a fifty-two week low of $435.27 and a fifty-two week high of $643.99. The company has a market cap of $217.48 billion, a PE ratio of 31.64, a P/E/G ratio of 2.39 and a beta of 0.84. The company has a debt-to-equity ratio of 0.74, a quick ratio of 1.18 and a current ratio of 1.55. The business has a 50-day simple moving average of $529.37 and a two-hundred day simple moving average of $508.75.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings data on Thursday, July 23rd. The medical research company reported $6.03 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.71 by $0.32. The firm had revenue of $11.99 billion for the quarter, compared to the consensus estimate of $11.71 billion. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. The company’s revenue for the quarter was up 10.5% compared to the same quarter last year. During the same quarter in the prior year, the company posted $4.28 earnings per share. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. As a group, equities analysts expect that Thermo Fisher Scientific Inc. will post 25.12 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, October 15th. Investors of record on Tuesday, September 15th will be given a $0.47 dividend. This represents a $1.88 annualized dividend and a dividend yield of 0.3%. The ex-dividend date of this dividend is Tuesday, September 15th. Thermo Fisher Scientific’s dividend payout ratio is presently 10.11%.

Insider Buying and Selling

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction dated Thursday, August 6th. The stock was sold at an average price of $574.47, for a total transaction of $5,744,700.00. Following the completion of the sale, the chief executive officer owned 123,925 shares of the company’s stock, valued at approximately $71,191,194.75. The trade was a 7.47% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Joseph R. Holmes sold 420 shares of the stock in a transaction dated Friday, August 7th. The shares were sold at an average price of $584.81, for a total value of $245,620.20. Following the completion of the transaction, the chief accounting officer directly owned 2,966 shares in the company, valued at $1,734,546.46. This represents a 12.40% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 52,053 shares of company stock worth $30,643,589 over the last three months. Corporate insiders own 0.33% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on the company. Evercore set a $570.00 target price on Thermo Fisher Scientific in a report on Monday, July 6th. Sanford C. Bernstein started coverage on Thermo Fisher Scientific in a research note on Friday, June 26th. They set a “market perform” rating and a $520.00 price objective for the company. HSBC lowered Thermo Fisher Scientific from a “buy” rating to a “hold” rating and cut their target price for the company from $670.00 to $540.00 in a research note on Wednesday, June 3rd. Wolfe Research initiated coverage on shares of Thermo Fisher Scientific in a research report on Tuesday, June 2nd. They set an “outperform” rating and a $535.00 price target for the company. Finally, Robert W. Baird cut their price objective on shares of Thermo Fisher Scientific from $653.00 to $639.00 and set an “outperform” rating on the stock in a research report on Friday, April 24th. One research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $619.41.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.